Purpose: The age at epilepsy onset in patients with inborn or very early acquired brain lesions depends on the epileptogenic potential of the lesion and the patients' individual "susceptibility" to epileptic seizures. To gain insight into these determinants, we analysed the case history of patients with focal cortical dysplasias (FCDs) and neuroglial tumours. Methods: In a systematic, retrospective analysis comprised of 233 patients who underwent surgery (116 with FCDs and 117 with neuroglial tumours), we evaluated the age at epilepsy onset according to histopathologic subgroups, lesion location and family history. Results: Epilepsy onset was significantly earlier in patients with FCD than for those with neuroglial tumours (FCDs: 8.06 AE 0.74 years, gangliogliomas: 15.86 AE 1.24 years, dysembryoplastic neuroepithelial tumours (DNTs): 19.18 AE 2.47 years; p < 0.00001). FCDs were most frequently located in the frontal, whereas neuroglial tumours most frequently in the temporal lobe. For FCD patients, the age at epilepsy onset was not dependent on lesion location, whereas DNTs in a temporal location were associated with a later epilepsy onset than gangliogliomas and extratemporal DNTs. A positive family history for epilepsy or epileptic seizures was found more frequently among patients with FCDs (FCDs: 20.4%, neuroglial tumours: 8.1%; p = 0.013). Conclusion: We postulate that the age difference at epilepsy onset between patients with FCDs and neuroglial tumours can be attributed -at least partially -to unidentified genetic factors underlying the epileptogenic potential of the brain tissue. Additionally, the large variance in the age at epilepsy onset is possibly also genetically determined.
Introduction
Age at epilepsy onset varies characteristically among distinct etiologic groups of epilepsy. Well-known examples include agerelated epilepsy syndromes such as benign partial epilepsy of childhood, childhood absence epilepsy (CAE) and juvenile myoclonic epilepsy (JME), etc [1, 2] . Whereas these examples supposedly have a genetic background, symptomatic epilepsies are rarely coupled to specific ages, and generally show a broader distribution regarding age at epilepsy onset. However, inborn brain lesions, either vascular or inflammatory in origin, or malformations of cortical and brain development may also show a strong connection to certain age groups with respect to epilepsy onset.
Focal cortical dysplasias (FCDs) are generally interpreted as a subgroup of malformations of cortical development (MCD), and are supposedly related to early developmental defects in the brain. Anomalies in proliferation of neuronal precursor cells, neuronal migration and cortical organisation can all contribute to the development of FCDs [3] [4] [5] . The currently accepted histopathologic classification scheme (Palmini-Taylor classification [4] underlies the diversity of FCDs at a cellular level and the different grades of disorganization in cortical structure; types Ia and Ib display cortical lamination defects and facultatively giant neurons, while type IIa and IIb exhibit dysmorphic and/or balloon cells [4] . Recent research has revealed possible genetic mechanisms which, in rare instances, underlie the formation of FCDs, especially the DEPDC5-pathway and its components NPRL2, NPRL3, PI3K and AKT [6, 5, [7] [8] [9] [10] ; reviewed by Neubauer and Hahn [11] . An overlap between the described genetic factors and the genetic background of tuberous sclerosis (TS) leading to overactivation of the mTORsignalling pathway is also well known, and reflects similarities in cellular abnormalities found both in FCD type IIb and TS lesions (TS cells referring to balloon cells in the histopathologic terminology, [5] . The epileptogenic potential of FCDs is thought to be different according to histopathologic subtypes [12] . This is partly because of the differential electrical activity of distinct cellular constituents (dysmorphic neurons are electrically active; balloon cells are silent, [13] , and most likely due to the extent and form of the "wiring" that connects pathologic with normal brain tissue. The versatility of FCDs is also reflected by the various epilepsy surgery outcomes [14] [15] [16] [17] [18] .
Neuroglial (or glioneural) tumours are also thought to arise during the early stages of brain maturation. The two main histopathologic types -gangliogliomas and dysembryoplastic neuroepithelial tumours (DNT) -are frequent causes of pharmacoresistant epilepsy [19, 20] . As with FCDs, epilepsy surgery often results in seizure freedom for patients with neuroglial tumours [21] [22] [23] [24] [25] [26] [27] . Over the past few years, investigations have revealed possible genetic factors underlying the development of neuroglial tumours, especially that of the BRAF- [28] [29] [30] and PI3K-pathway [31] for gangliogliomas, and the FGFR1-pathway for DNTs [32, 33] . Apart from these molecular signalling routes, distinct profiles of chromosomal copy number aberrations have also been described in neuroglial tumours [34] .
Even though the clinical practice clearly distinguishes between FCDs and neuroglial tumours, there is emerging evidence that the development of FCDs and neuroglial tumours may share common pathways [35, 6, 31] , and gangliogliomas may be interpreted in the context of mTORpathies as well (reviewed by Lim & Crino [5] . This notion is also supported by histopathologic findings wherein neuroglial tumours and FCDs coexist in close proximity [36] , thus leading to the formation of a so-called FCD III [37] .
The epileptogenic potential of these lesions, and as a consequence the age at epilepsy onset, however, cannot be directly deduced from the above described genetic factors. Additionally, common experience reflects a broad age distribution with respect to age at epilepsy onset in respective patients. Further determinants influencing epileptogenicity can be genetic as well as nongenetic mechanisms. In this study, we aimed at unveiling the variables influencing age at epilepsy onset, and gaining further insight into possible, but yet unknown, genetic and non-genetic mechanisms influencing the development of epilepsy.
Methods
We retrospectively evaluated the clinical history of 233 patients who underwent epilepsy surgical resection between 2000 and 2016 in the Epilepsy Centre of Bonn, Germany, and in whom a histopathologic evaluation confirmed the diagnosis of either an FCD or neuroglial tumour. The histopathologic (i.e. neuropathologic) evaluation was performed in the Department of Neuropathology of the University of Bonn Medical Centre, Germany. For the classification of FCDs, the Palmini-Taylor system was adopted [4] . In patients undergoing surgery before 2004, the histopathologic evaluation of the FCDs relied on the documented presence of TScells and additional characteristics described in the histopathology protocol. Gangliogliomas and DNTs were further subclassified according to the WHO system (see review of Holthausen and Blümcke [38] ).
Overall, 116 patients with FCDs (25 with FCD IIa and 81 with FCD IIb; in the remaining 10 cases the histopathology either revealed FCD I or was not informative enough for further classification), 89 patients with gangliogliomas, and 28 patients with DNTs were included in our analysis. For the evaluation, we excluded patients with dual pathologies (for instance, associated hippocampal sclerosis in conjunction with neuroglial tumours in the temporal lobe); patients where the result of histopathologic examinations was discordant with that of previous interventions (in a few cases, resective surgery or a biopsy prior to surgery in our center); and patients with alternative etiologies for epilepsy (i.e. one patient with coexistent SCN1A-mutation). The age at epilepsy onset (i.e. index seizure) was assessed based on patient charts and records. In most cases, at least two independent sources with concordant results were required for inclusion in our study. Statistical analysis was performed with the statistical toolbox of MATLAB (MathWorks, Natick, USA). Within the framework of the descriptive statistics, cumulative and differential distribution functions (histograms) were computed to evaluate the age spectrum of the index seizure in different histopathologic categories. The statistical significance of differences between age distributions were evaluated with T-test, Mann-Whitney-U test, Kruskal-Wallis test, and 2-way ANOVA depending on distribution characteristics of the examined variables and the number of compared distributions. Data were presented as mean values and standard errors of the mean, if not otherwise indicated. P-values below 0.05 were accepted as significant. Normality of distributions was assessed with a Lilliefors-test. As the majority of FCDs were located in the frontal lobe and most of the neuroglial tumours were within the temporal lobe, lesions in other lobes were summed up as "nonfrontal" and "extratemporal" respectively in order to avoid larger differences in sampling size. Differences in interregional distributions of lesions and in the family history of the respective patients were evaluated with Pearson's Chi2 statistics.
Results
We evaluated the clinical history of 116 patients with FCDs, 89 patients with gangliogliomas and 28 patients with DNTs who underwent epilepsy surgery between 2000 and 2016 after an extensive presurgical evaluation at the Department of Epileptology, University of Bonn Medical Centre, Germany. Characteristic histopathologic features of these lesions are shown in Fig. 1 . Basic characteristics of the patient groups (sex, age at epilepsy onset, exact histopathologic type of lesion, location) are outlined in Table 1 . Age at epilepsy onset displays a wide spectrum ranging from the first up to 43rd years of age for FCDs, and from the first up to the 60th years of age for neuroglial tumours ( Fig. 2A and B, displaying histograms for FCDs and neuroglial tumours). In both cases, the evaluation of the histograms suggests that diverse subgroups may exist. Compared to patients with gangliogliomas and DNTs, the age at epilepsy onset was significantly earlier for patients with FCDs. However, the difference was not significant between the two histopathologic categories of neuroglial tumours (8.06 AE 0.74 years for 116 patients with FCD; 15.86 AE 1.24 years for 88 patients with ganglioglioma and 19.18 AE 2.47 years for 28 patients with DNT; p < 0.00001, Kruskal-Wallis test with post hoc Tukey-Kramer adjustment for multiple comparisons; see Fig. 3A and B).
To evaluate the relevance of different histopathologic FCD subgroups as a possible variable influencing age at epilepsy onset, we also examined the variables in the groups with FCD type IIa and IIb, but this analysis did not reveal any differences (9.08 AE 1.66 years for 25 patients with FCD IIa and 7.60 AE 0.90 years for 81 patients with FCD IIb; p = 0.22, Mann-Whitney-U test). Among neuroglial tumours the overwhelming majority belonged to WHO grade I (112 patients), higher grade developmental tumours were very rare (from the group of gangliogliomas 4 with grade II, 1 with grade III, DNTs were all grade I).
There was no hint at gender differences regarding age at epilepsy onset in distinct histopathologic subgroups (p = 0.71 for FCDs, Mann-Whitney-U test; p = 0.07 for gangliogliomas, MannWhitney-U test; and p = 0.80 for DNTs, T-test; for more detail see Table 1 ).
FCDs were predominantly localized to the frontal lobe and appeared less frequently in temporal and occipital locations (71 frontal, 16 parietal, 9 temporal, 3 occipital, 16 multilobar or insular FCDs), whereas the preferential location of both gangliogliomas and DNTs was the temporal lobe (82 temporal, 11 frontal, 5 parietal, 4 occipital and 15 multilobar or insular locations). Differences in regional distributions of FCDs and neuroglial tumours also reached a statistical significance (p < 0.000001, Pearson's Chi2-test). Regional distributions of FCDs for types IIa and IIb did not differ significantly (p = 0.50, Pearson's Chi2-test; FCD IIa: 16 frontal, 3 parietal, 3 temporal, 1 occipital and 2 multilobar or insular locations; FCD IIb: 50 frontal, 13 parietal, 3 temporal, 2 occipital and 12 multilobar or insular locations). On the other hand, regional distributions in the group of neuroglial tumours were somewhat different. Even though gangliogliomas and DNTs were most frequently located in the temporal lobe, frontal locations among DNTs were found relative frequently (p < 0.01, Pearson's Chi2-test; gangliogliomas: 67 temporal, 3 frontal, 3 parietal, 3 occipital and 13 multilobar or insular locations; DNTs: 15 temporal, 8 frontal, 2 parietal, 1 occipital and 2 multilobar locations).
Lesions of the same histological subgroup may have different epileptogenic potentials according to their distinct location in the brain, and the properties of the network with which they interact. Therefore, we examined the age at epilepsy onset in the "preferential" and "non-preferential" locations of FCDs and neuroglial tumours. Even though the difference between FCDs in frontal versus nonfrontal locations was not significant (7. ; p = 0.26 for histology effect, p = 0.012 for location effect, and p = 0.019 for interaction effects, 2-way ANOVA with post hoc multiple comparisons). Because FCDs in the temporal and occipital lobes and neuroglial tumours in parietal and occipital locations were rare, we were unable to perform a more detailed analysis for distinct lobes.
In order to gain more insight into possible genetic components determining age at epilepsy onset, we also evaluated the family history for epileptic seizures or epilepsy in the respective patient collectives. For 98 of the 116 patients with FCD, we had reliable Table 2 . The trend for more frequent positive family history in the group of FCD patients reached statistical significance (p = 0.013, Pearson's Chi2-test). On the other hand, no statistically significant differences were found when comparing the age at epilepsy onset with positive versus negative family history either for FCDs (8.55 AE 2.15 years with positive and 8.68 AE 0.90 years with negative family history; p = 0.32, Mann-Whitney-U test) or neuroglial tumours (14.63 AE 3.45 years with positive and 17.59 AE 1.33 years with negative family history; p = 0.57, Mann-Whitney-U test). This held also true when we performed a subtype-specific analysis for FCDs (5.50 AE 2.04 years for 8 FCD IIa in patients with positive, 12.08 AE 2.69 years for 13 FCD IIa in patients with negative, 10.58 AE 3.26 years for 12 FCD IIb in patients with positive and 7.86 AE 0.99 years for 59 FCD IIb in patients with negative family history; p = 0.85 for histology effect, p = 0.40 for family history effect and p = 0.046 for interaction effects, 2-way ANOVA, post hoc comparisons not revealing any statistically significant difference). Since there were only 2 patients with DNT and a positive family history for epileptic seizures, we did not perform a more detailed analysis of neuroglial tumours.
Discussion
FCDs and neuroglial tumours are presumed to be either inborn brain lesions or lesions which are acquired at a very early age. Both types of lesions frequently result in an epilepsy which is difficultto-treat from a pharmacological standpoint. Even though the epileptogenic lesion resides in the brain from an early age on, the question arises as to why some patients develop seizures very early while others only at a relatively "old" age. In this study, we Table 1 Basic characteristics of the analysed patient groups with histologically proven FCDs, gangliogliomas and DNTs. * In a few cases FCDs were classified as FCD I or a precise classification was not possible. ** In one case the precise location of an FCD of central location could not be determined unequivocally (precentral versus postcentral). *** As WHO grades II and III were very rare among gangliogliomas, age at onset was not analysed separately for WHO grades. DNTs were all grade I. Age at onset is shown for precise classifications only. analysed the age at epilepsy onset in patients with histologically proven FCDs, gangliogliomas and DNTs. Some epileptic events might not be immediately recognised as epilepsy. One reason for this is that patients often wait longer before seeking for further medical evaluation [39] , and this phenomenon can lead to biases in epidemiological observational studies. Patients in our center are interviewed by specialists who are well-trained in epileptology and the interview is always comprised of a very detailed description of seizures and seizure semiologies. Therefore, it is rather unlikely that significant discrepancies exist between the reported and exact onset of epilepsy in the respective cohorts.
FCD
Whereas the age spectrum is quite broad in each case (ranging from the first to the 43rd years in patients with FCDs and from the first to the 60th years in patients with neuroglial tumours), patients with FCD tended to develop epilepsy earlier than patients with neuroglial tumours, as also reported in the literature [40, 47] . In addition, one might speculate that in each group different patient subgroups exist with different "predilection" age for epilepsy onset. As also described in the literature, preferential locations of FCDs are the frontal (meaning frontal and precentral locations) [40, 16] , and that of neuroglial tumours are the temporal lobes [20, 22, 25, 27, 47] . Different lesion locations (lobes) did not have a statistically significant impact on the age at epilepsy onset in case of FCDs, and were associated with a later age at epilepsy onset in case of temporal DNTs. A significantly different relation of distinct histopathologic subtypes of FCDs (type IIa and IIb) to epilepsy onset seems -based on the actual results -not reasonable.
However, at this point we need to emphasise that our study has a couple of restrictions. First of all, lesions in "noncanonical" locations (meaning FCDs outside the frontal and neuroglial tumours outside the temporal lobe) were infrequent and difficult to handle in a reasonable manner for statistics. Besides, FCD type II (meaning type IIa and IIb) is overrepresented among our patients, so our conclusions refer only to patients with these histopathological subgroups. This bias and the high percentage of FCD type IIb may be explained by circumstances in the presurgical evaluation, where patients with well-defined or more circumscribed lesions on MRI and more circumscribed focal epileptiform activity in EEG studies could have been preferentially selected as "optimal" candidates for epilepsy surgery. In addition, the groups with FCD type IIa and DNT were significantly smaller than those with FCD IIb and ganglioglioma, therefore results concerning these groups need to be interpreted cautiously. One possible reason as to why FCDs tend to cause epilepsy at earlier age may be related to the fact that FCDs are inborn malformations of cortical development (MCD) where the lesion has an epileptogenic potential from early ages on. On the other hand, neuroglial tumours might show a slight growth tendency and require more time to reach a certain "epileptogenic threshold". An alternative explanation for the observed differences could be that neural elements of FCDs can be integrated in electrically active networks and cause network dysfunction and epileptic seizures in a direct manner, while cellular elements of neuroglial tumours are considered rather inactive, and the epileptogenic potential of these tumours resides in their indirect interaction with neighbouring brain tissue (reviewed by Fernández and Loddenkemper [41] ). Supporting this hypothesis, the intrinsic epileptogenicity of cortical dysplasias seems much higher than that of neuroglial tumours [42, 12, 43] . Another possible explanation for the observed effects involves the ongoing maturation of brain regions and of subcortical connections which often extends into adulthood, and the diverse kinetics of these processes in distinct anatomical structures [44] . Parallel to physiological networks, the time necessary for the development of pathological and epileptogenic networks may vary according to the type of lesion and its location.
Our analysis does not satisfactorily explain the huge variability in age at epilepsy onset among the examined groups. Interestingly, a positive family history for epilepsy or epileptic seizures was observed more frequently in the patient group with FCDs than for the neuroglial tumour group. This observation must be interpreted with precaution in view of the relatively small number of cases and the heterogeneity of the epileptic manifestations in the affected families. However, it also supports the hypothesis that -besides the above described and wellknown, but also rather rare genetic defects -further genetic factors may influence the epileptogenic potential of lesions, the individual susceptibility of patients to seizures and as a consequence of these the age at epilepsy onset in patients with FCDs and neuroglial tumours. A recent report also emphasizes that genetic alterations of the mTOR-pathway as well as of SCN1A and GABRG2 genes are relatively common in patients with nonlesional focal epilepsy and a positive family history for epileptic seizures, and the age at epilepsy onset shows a correlation with the presence of these alterations [45] . In addition to genetic routes, epigenetic mechanisms can also contribute to the different epileptogenic potential of these lesions (reviewed by Kobow and Blümcke [46] ). In summary, further intense investigations are warranted to precisely identify the genetic and non-genetic influences shaping the evolution of epilepsy in patients with FCDs and neuroglial tumours. The broad spectrum of age at epilepsy onset not only reflects the differences in the epileptogenic potential of these lesions, but also the differences in individual patient susceptibility to epileptic seizures. Altogether we assume that besides the above mentioned and supposed genetic and non-genetic variables, several other factors influence the evolution of epilepsy.
Conclusion
The age at epilepsy onset in patients with structural epilepsy can vary remarkably according to the underlying pathology. In this study, we evaluated patients who underwent surgery for histologically proven FCDs and neuroglial tumours. According to our results, FCDs lead to an earlier epilepsy onset than neuroglial tumours. Nevertheless, the age spectrum of epilepsy onset is very broad for both of these patient groups. At present, we could not positively identify further variables for determining age at epilepsy onset in these patient groups. However, the higher relative incidence of a positive family history for epileptic seizures or epilepsy in patients with FCDs suggests possible and unknown genetic factors influencing the epileptogenic potential of these brain alterations and the individual susceptibility of patients to epileptic seizures. Further clarification of these mechanisms and detailed analysis of currently known pathways (such as the mTORpathway) can lead to a better understanding of the pathophysiology of these patients and could open new therapeutic avenues.
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